Illumina, Inc. (FRA:ILU)
Market Cap | 12.45B |
Revenue (ttm) | 3.66B |
Net Income (ttm) | 1.07B |
Shares Out | n/a |
EPS (ttm) | 6.75 |
PE Ratio | 11.60 |
Forward PE | 20.17 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 6 |
Average Volume | 42 |
Open | 77.36 |
Previous Close | 78.03 |
Day's Range | 77.36 - 79.59 |
52-Week Range | 62.29 - 146.32 |
Beta | n/a |
RSI | 33.81 |
Earnings Date | Oct 31, 2025 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.
Financial numbers in USD Financial StatementsNews

ILMN Stock vs. IQV Stock
Amid increased competition from China's MGI Tech, Illumina's stock (NASDAQ: ILMN) has dropped by 11% in a week. MGI Tech's DNA sequencers are reportedly gaining market share, and despite a recent decl...

Illumina advances personalized cancer care with new pharma development partnerships
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO , Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) will partner with mult...

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D...
Bullish Two Hundred Day Moving Average Cross - ILMN
In trading on Tuesday, shares of Illumina Inc (Symbol: ILMN) crossed above their 200 day moving average of $101.59, changing hands as high as $102.00 per share. Illumina Inc shares are currently tradi...

CDC vaccine panel to meet this week: Here's what's at stake
Scott Gottlieb, former FDA commissioner and current board member of Pfizer and Illumina, joins CNBC's 'Squawk on the Street' to discuss expectations for a CDC panel's review of vaccines this week, wha...
ILMN January 2028 Options Begin Trading
Investors in Illumina Inc (Symbol: ILMN) saw new options begin trading today, for the January 2028 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is...

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says
DNA sequencers from Chinese firm MGI Tech can rival those from global market leader Illumina in spite of US sanctions, according to Yin Ye, CEO of BGI Group, former parent of the Shenzhen-based biotec...

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, custome...

mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
What Does the Market Think About Illumina?
Illumina's (NYSE: ILMN) short percent of float has risen 12.85% since its last report. The company recently reported that it has 7.89 million shares sold short , which is 7.64% of all regular shares ...
Illumina: The Stock Is Still Undervalued

Illumina (ILMN) Q2 2025 Earnings Call Transcript

Illumina (ILMN) Q2 EPS Jumps 9%

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results
Illumina, Inc. (NASDAQ: ILMN) reported better-than-expected earnings for the second quarter on Thursday . The company posted quarterly earnings of $1.19 per share which beat the analyst consensus est...

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results
Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday.
Illumina raises 2025 revenue and EPS guidance as clinical demand strengthens and multiomics acquisition advances
Illumina, Inc. 2025 Q2 - Results - Earnings Call Presentation
Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript

Illumina: A 5.2 Rating Amid Challenges and Opportunities
Illumina reports a decline in revenue despite beating estimates

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025
Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis GAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025 GAAP diluted...

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling
Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research and clinical...

Illumina Stock: What Went Wrong And Why It's Best To Stay Away
Illumina Inc. (NASDAQ: ILMN) is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that...

Illumina Stock: What Went Wrong And Why It's Best To Stay Away
Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond ...